Back

Integrated Molecular Profiling of Rhabdomyosarcoma Subtypes by Targeted RNAseq

Avenarius, M. R.; Patton, A.; Mohamed, N.; Pan, X.; Jones, D.

2024-10-14 genetic and genomic medicine
10.1101/2024.10.11.24315314 medRxiv
Show abstract

All subtypes of rhabdomyosarcoma (RMS) show skeletal muscle differentiation but each has different oncogenic mechanisms including recurrent PAX3 and PAX7 gene fusions (alveolar), a hotspot mutation in MYOD1 (spindle/sclerosing) and mutations in other oncogenes and tumor suppressors (embryonal, pleomorphic). This range of genomic findings typically requires several different DNA and RNA-based diagnostic assays. Here, we utilize a clinically validated, targeted RNA next-generation sequencing (RNAseq) panel to simultaneously detect MYOD1 transcript levels for lineage assignment, PAX3 and PAX7 translocations and mutations in MYOD1 and other RMS-related genes for definitive subtyping in a single assay. RNA-based detection of MYOD1 p.L122R and other mutations were orthogonally validated with digital droplet (dd)PCR or DNA-based NGS. Expanding the utility of clinical-grade RNAseq data beyond the detection of gene fusions is a cost-effective and time-efficient approach for more comprehensive screening of RMS. Impact statementComprehensive and rapid molecular diagnostics is a key driver in the selection and initiation of targeted therapies.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.